Aravofloxacin
(Redirected from JNJ-Q2)
A fluoroquinolone antibiotic
Aravofloxacin is a fluoroquinolone antibiotic that was under development for the treatment of bacterial infections. It is a synthetic antibacterial agent that belongs to the class of quinolone antibiotics, which are known for their broad-spectrum activity against a variety of Gram-positive and Gram-negative bacteria.
Mechanism of Action[edit | edit source]
Aravofloxacin, like other fluoroquinolones, works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes that are essential for bacterial DNA replication, transcription, and repair. By interfering with these critical processes, aravofloxacin effectively halts bacterial cell division and leads to cell death.
Pharmacokinetics[edit | edit source]
Aravofloxacin is designed to be administered orally, and it exhibits good absorption from the gastrointestinal tract. Once absorbed, it is distributed throughout the body, reaching effective concentrations in various tissues and fluids. The drug is primarily eliminated through the kidneys, and its half-life allows for convenient dosing schedules.
Clinical Development[edit | edit source]
Aravofloxacin was being developed for the treatment of community-acquired pneumonia and other respiratory tract infections. However, its development was discontinued during clinical trials. The reasons for discontinuation are not publicly detailed, but it is common for drug development to be halted due to issues such as lack of efficacy, safety concerns, or strategic business decisions.
Potential Uses[edit | edit source]
Although aravofloxacin is not currently available on the market, its broad-spectrum activity suggests potential utility in treating infections caused by resistant bacterial strains. Fluoroquinolones are often used in cases where other antibiotics are ineffective, making them valuable in the fight against antibiotic resistance.
Safety and Side Effects[edit | edit source]
As with other fluoroquinolones, aravofloxacin may be associated with side effects such as gastrointestinal disturbances, central nervous system effects, and potential tendon damage. The safety profile of aravofloxacin would have been thoroughly evaluated during its clinical trials.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
